MX2021014728A - Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada. - Google Patents
Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada.Info
- Publication number
- MX2021014728A MX2021014728A MX2021014728A MX2021014728A MX2021014728A MX 2021014728 A MX2021014728 A MX 2021014728A MX 2021014728 A MX2021014728 A MX 2021014728A MX 2021014728 A MX2021014728 A MX 2021014728A MX 2021014728 A MX2021014728 A MX 2021014728A
- Authority
- MX
- Mexico
- Prior art keywords
- dimethyltryptamine
- deuterated
- compositions
- present
- partially
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se relaciona con composiciones que comprenden N,N-dimetiltriptamina, N,N-dimetiltriptamina deuterada y/o N,N-dimetiltriptamina parcialmente deuterada. En particular, la presente invención se relaciona con composiciones que comprenden una combinación de N,N-dimetiltriptamina y el 2% o más en peso de uno o más compuestos N,N-dimetiltriptamina deuterada seleccionado de a,a-dideutero-N,N-dimetiltriptamina y a,a,ß,ß-tetradeutero-N,N-dimetiltriptamina. Las composiciones adicionales y alternativas de la presente invención comprenden una combinación del compuesto N,N-dimetiltriptamina seleccionado de a,ß,ß-trideutero-N,N-dimetiltriptamina, a,ß-dideutero-N,N-dimet iltriptamina y a-deutero-N,N-dimetiltriptamina. También se proporcionan para sintetizar composiciones de la presente invención y métodos de uso de las composiciones descritas en la presente en el tratamiento de trastornos psicocognitivos, tales como el trastorno depresivo mayor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1907871.6A GB201907871D0 (en) | 2019-06-03 | 2019-06-03 | Therapeutic compositions |
| PCT/EP2020/065244 WO2020245133A1 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014728A true MX2021014728A (es) | 2022-03-11 |
Family
ID=67385960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014728A MX2021014728A (es) | 2019-06-03 | 2020-06-02 | Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11771681B2 (es) |
| EP (2) | EP4062910A1 (es) |
| JP (1) | JP2022535093A (es) |
| KR (1) | KR20220034061A (es) |
| CN (1) | CN114096246A (es) |
| AU (1) | AU2020286709B2 (es) |
| BR (1) | BR112021024333A2 (es) |
| CA (2) | CA3142290A1 (es) |
| DK (1) | DK3826632T3 (es) |
| EA (1) | EA202193338A1 (es) |
| ES (1) | ES2922101T3 (es) |
| GB (4) | GB201907871D0 (es) |
| HR (1) | HRP20220837T8 (es) |
| HU (1) | HUE059439T2 (es) |
| IL (1) | IL288617A (es) |
| MX (1) | MX2021014728A (es) |
| PL (1) | PL3826632T3 (es) |
| PT (1) | PT3826632T (es) |
| TW (1) | TW202210075A (es) |
| WO (1) | WO2020245133A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| CN114829340B (zh) | 2019-11-07 | 2023-12-12 | 斯玛尔药物有限公司 | 化合物 |
| BR112022015379A2 (pt) | 2020-02-04 | 2022-09-27 | Mindset Pharma Inc | Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc |
| MX2022009526A (es) | 2020-02-04 | 2022-11-08 | Mindset Pharma Inc | Derivados de psilocina como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
| CN115667217A (zh) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | 氘化的色胺衍生物和使用方法 |
| US20210378969A1 (en) | 2020-06-02 | 2021-12-09 | Small Pharma Ltd. | Therapeutic solid dosage forms |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| IL298541B1 (en) * | 2020-06-02 | 2024-04-01 | Cybin Uk Ltd | 1,1-dideuterio-2-(1H-indol-3-yl)-N,N-bis(trideuteriomethyl)ethanamine and a medical preparation containing it |
| WO2021116503A2 (en) * | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| GB2605144A (en) * | 2021-03-22 | 2022-09-28 | Small Pharma Ltd | Deuterated compounds |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| WO2022117359A1 (en) | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| EP4255422A1 (en) * | 2020-12-03 | 2023-10-11 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| JP2024508922A (ja) * | 2021-03-02 | 2024-02-28 | マインドセット ファーマ インコーポレイテッド | セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 |
| CA3216889A1 (en) * | 2021-04-26 | 2022-11-03 | Glenn Short | Novel n,n-dimethyltryptamine compositions and methods |
| AU2022268420A1 (en) * | 2021-05-05 | 2023-12-21 | Kare Chemical Technologies Inc. | Catalytic tryptamine processes and precursors |
| EP4340809A1 (en) * | 2021-05-17 | 2024-03-27 | Cybin IRL Limited | Formulations of psilocybin |
| CA3220850A1 (en) * | 2021-06-02 | 2022-12-08 | Jason WALLACH | Fluorinated tryptamine compounds, analogues thereof, and methods using same |
| CA3229044A1 (en) | 2021-08-12 | 2023-02-16 | Kuleon Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| WO2023028092A2 (en) * | 2021-08-23 | 2023-03-02 | Alexander Shulgin Research Institute | Fluorinated empathogens |
| WO2023028091A1 (en) * | 2021-08-23 | 2023-03-02 | Alexander Shulgin Research Institute | Deuterated empathogens |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159201A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| EP4159192A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
| WO2023076135A1 (en) * | 2021-10-29 | 2023-05-04 | Psilera Inc. | N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same |
| AU2022393234A1 (en) | 2021-11-18 | 2024-06-06 | Cybin Uk Ltd | Injectable and inhalable formulations |
| WO2023129956A2 (en) | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023186867A1 (en) * | 2022-03-31 | 2023-10-05 | Cybin Irl Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336378A (en) | 1980-04-10 | 1982-06-22 | Sandoz, Inc. | Isoxazolyl indolamines |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| AU6689601A (en) | 2000-06-16 | 2002-01-02 | Rtp Pharma Inc | Improved injectable dispersions of propofol |
| WO2004085392A1 (en) | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
| EP2081893B1 (en) | 2006-10-19 | 2011-03-23 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| US20090076121A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched sumatriptan |
| WO2009049030A1 (en) | 2007-10-09 | 2009-04-16 | Triton Biopharma, Llc | Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter |
| US20100069399A1 (en) * | 2008-09-15 | 2010-03-18 | Auspex Pharmaceutical, Inc. | Arylpiperazine modulators of d2 receptors, 5-ht1a receptors, and/or 5-ht2a receptors |
| JP7273731B2 (ja) | 2017-02-09 | 2023-05-15 | カームテック、エルエルシー | シロシビン誘導体を含む組成物及び方法 |
| US20200147038A1 (en) | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| CN109251151A (zh) * | 2017-07-12 | 2019-01-22 | 北京广为医药科技有限公司 | N-(2-(取代-萘-1-基)乙基)取代酰胺类化合物、其制备及其用途 |
| WO2019081764A1 (en) * | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS |
| WO2019089902A1 (en) | 2017-11-01 | 2019-05-09 | Drexel University | Compounds, compositions, and methods for treating diseases |
| CA3130180A1 (en) | 2019-02-22 | 2020-08-27 | Theis Terwey | Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders |
| DK3927337T3 (da) | 2019-02-22 | 2024-04-22 | Gh Res Ireland Limited | 5-Methoxy-N,N-dimethyltryptamin (5-MeO-DMT) til behandling af svær depression |
| AU2020228289A1 (en) | 2019-02-27 | 2021-09-09 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
| CN113784962A (zh) | 2019-02-27 | 2021-12-10 | 加利福尼亚大学董事会 | 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环 |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| CN114829340B (zh) | 2019-11-07 | 2023-12-12 | 斯玛尔药物有限公司 | 化合物 |
| MX2022009526A (es) | 2020-02-04 | 2022-11-08 | Mindset Pharma Inc | Derivados de psilocina como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| CN115667217A (zh) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | 氘化的色胺衍生物和使用方法 |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| WO2021116503A2 (en) | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| US20210378969A1 (en) | 2020-06-02 | 2021-12-09 | Small Pharma Ltd. | Therapeutic solid dosage forms |
| GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| CN116056705A (zh) | 2020-08-05 | 2023-05-02 | 巴塞尔大学医院 | 用于dmt辅助心理疗法的静脉内dmt施用方法 |
| US20220062237A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| WO2022043227A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| CA3194558A1 (en) | 2020-10-02 | 2022-04-07 | Brett J. GREENE | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2019
- 2019-06-03 GB GBGB1907871.6A patent/GB201907871D0/en not_active Ceased
-
2020
- 2020-06-02 GB GB2008303.6A patent/GB2585978B/en active Active
- 2020-06-02 JP JP2021571882A patent/JP2022535093A/ja active Pending
- 2020-06-02 ES ES20731372T patent/ES2922101T3/es active Active
- 2020-06-02 HR HRP20220837TT patent/HRP20220837T8/hr unknown
- 2020-06-02 HU HUE20731372A patent/HUE059439T2/hu unknown
- 2020-06-02 CN CN202080050439.9A patent/CN114096246A/zh active Pending
- 2020-06-02 EP EP22173907.1A patent/EP4062910A1/en active Pending
- 2020-06-02 US US16/890,664 patent/US11771681B2/en active Active
- 2020-06-02 PL PL20731372.7T patent/PL3826632T3/pl unknown
- 2020-06-02 MX MX2021014728A patent/MX2021014728A/es unknown
- 2020-06-02 US US17/616,345 patent/US20220168275A1/en active Pending
- 2020-06-02 GB GB2100807.3A patent/GB2586940B/en active Active
- 2020-06-02 EA EA202193338A patent/EA202193338A1/ru unknown
- 2020-06-02 GB GB2107702.9A patent/GB2592822B/en active Active
- 2020-06-02 PT PT207313727T patent/PT3826632T/pt unknown
- 2020-06-02 KR KR1020217043410A patent/KR20220034061A/ko not_active IP Right Cessation
- 2020-06-02 BR BR112021024333A patent/BR112021024333A2/pt unknown
- 2020-06-02 DK DK20731372.7T patent/DK3826632T3/da active
- 2020-06-02 WO PCT/EP2020/065244 patent/WO2020245133A1/en unknown
- 2020-06-02 AU AU2020286709A patent/AU2020286709B2/en active Active
- 2020-06-02 EP EP20731372.7A patent/EP3826632B1/en active Active
- 2020-06-02 CA CA3142290A patent/CA3142290A1/en active Pending
- 2020-12-23 CA CA3104072A patent/CA3104072C/en active Active
-
2021
- 2021-06-01 TW TW110119792A patent/TW202210075A/zh unknown
- 2021-12-02 IL IL288617A patent/IL288617A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014728A (es) | Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada. | |
| MX2022005399A (es) | Compuestos. | |
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| MX2017016424A (es) | Compuestos para su uso en el tratamiento de trastornos neuromusculares. | |
| MX2019014974A (es) | Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson. | |
| PH12018500016A1 (en) | Agents, uses and methods for the treatment of synucleinopathy | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| EA201491819A1 (ru) | Фармацевтические композиции для комбинированного лечения | |
| MX2022006466A (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune. | |
| MX2017009824A (es) | Triazoles sustituidos y metodos relacionados a estos. | |
| MX2019009653A (es) | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos. | |
| MY196791A (en) | New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions | |
| MX2020000523A (es) | Compuestos de isocromano y usos de los mismos. | |
| MX2018013164A (es) | Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. | |
| EA201791829A1 (ru) | Амидные соединения в качестве агонистов рецептора 5-ht | |
| CR20210460A (es) | Compuestos útiles en la terapia del vih | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| MX2017015961A (es) | Moduladores alostericos positivos del receptor m1 muscarinico. | |
| MX2020008746A (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. | |
| SG10201907289VA (en) | Monomethylfumarate prodrug compositions | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| MX2019011558A (es) | Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| EA202091340A1 (ru) | Способ получения соединений "лекарственное средство-линкер" | |
| PH12020551620A1 (en) | Compositions for preventing or treating dry eye | |
| PH12020550549A1 (en) | Compositions for preventing or treating lupus |